|
2025 Journal Article Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancersGough, Madeline, Kwah, Kayden KX., Khan, Tashbib, Ghosh, Saikat, Sun, Biao, Lee, Catherine YJ., Sokolowski, Kamil A., Tse, Brian WC., Wickramasuriya, Lashith, Ferguson, Kaltin, Rogers, Rebecca, Goh, Justin B., Fletcher, Nicholas L., Houston, Zachary H., Thurecht, Kristofer J., Bray, Laura J., Liu, Cheng, Pyke, Christopher, Lim, Elgene, Snell, Cameron E., He, Yaowu, Hooper, John D. and Kryza, Thomas (2025). Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancers. Clinical Cancer Research, 31 (8), OF1-OF16. doi: 10.1158/1078-0432.ccr-24-2865 |
|
2024 Journal Article Aurora B inhibitors promote RB hypophosphorylation and senescence independent of p53-dependent CDK2/4 inhibitionVora, Shivam, Andrew, Ariel, Kumar, Ramyashree Prasanna, Nazareth, Deborah, Bonfim-Melo, Alexis, Lim, Yoon, Ong, Xin Yee, Fernando, Madushan, He, Yaowu, Hooper, John D., McMillan, Nigel A. J., Urosevic, Jelena, Travers, Jon, Saeh, Jamal, Kumar, Sharad, Jones, Mathew J. K. and Gabrielli, Brian (2024). Aurora B inhibitors promote RB hypophosphorylation and senescence independent of p53-dependent CDK2/4 inhibition. Cell Death & Disease, 15 (11) 810, 810. doi: 10.1038/s41419-024-07204-5 |
|
2024 Journal Article Identification and characterization of TM4SF1+ tumor self-seeded cellsYang, Haotian, Wang, Haolu, He, Yaowu, Yang, Yang, Thompson, Erik W., Xia, Di, Burke, Leslie J., Cao, Lu, Hooper, John D., Roberts, Michael S., Crawford, Darrell H.G. and Liang, Xiaowen (2024). Identification and characterization of TM4SF1+ tumor self-seeded cells. Cell Reports, 43 (7) 114512, 1-24. doi: 10.1016/j.celrep.2024.114512 |
|
2024 Journal Article Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cellsShah, Esha T., Molloy, Christopher, Gough, Madeline, Kryza, Thomas, Samuel, Selwin G., Tucker, Amos, Bhatia, Maneet, Ferguson, Genevieve, Heyman, Rebecca, Vora, Shivam, Monkman, James, Bolderson, Emma, Kulasinghe, Arutha, He, Yaowu, Gabrielli, Brian, Hooper, John D., Richard, Derek J., O’Byrne, Kenneth J. and Adams, Mark N. (2024). Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells. British Journal of Cancer, 130 (7), 1196-1205. doi: 10.1038/s41416-024-02584-z |
|
2023 Journal Article MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrierMcGuckin, Michael A., Davies, Julie M., Felgner, Pascal, Wong, Kuan Yau, Giri, Rabina, He, Yaowu, Moniruzzaman, Md., Kryza, Thomas, Sajiir, Haressh, Hooper, John D., Florin, Timothy H., Begun, Jakob, Oussalah, Abderrahim, Hasnain, Sumaira Z., Hensel, Michael and Sheng, Yong H. (2023). MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrier. Cellular and Molecular Gastroenterology and Hepatology, 16 (6), 985-1009. doi: 10.1016/j.jcmgh.2023.08.011 |
|
2023 Conference Publication Structural basis of an anti-cancer biological warhead bound to its target CDCP1 for the diagnosis and treatment of epithelial cancersKwah, Kayden, Gu, Weixi, Arachchige, Kasun S. A., He, Yaowu, Landsberg, Michael, Kobe, Bostjan and Hooper, John (2023). Structural basis of an anti-cancer biological warhead bound to its target CDCP1 for the diagnosis and treatment of epithelial cancers. XXVI IUCr Congress, Melbourne, VIC Australia, 22-29 August 2023. Hoboken, NJ United States: Wiley-Blackwell. doi: 10.1107/s2053273323084449 |
|
2023 Conference Publication Development of a CUB domain-containing protein 1 (CDCP1)-targeting antibody-drug conjugate for triple-negative and metastatic breast cancerGough, Madeline, Kwah, Kayden, He, Yaowu, Snell, Cameron Edward, Hooper, John D. and Kryza, Thomas (2023). Development of a CUB domain-containing protein 1 (CDCP1)-targeting antibody-drug conjugate for triple-negative and metastatic breast cancer. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology (ASCO). doi: 10.1200/jco.2023.41.16_suppl.e15012 |
|
2023 Journal Article Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinomaRaninga, Prahlad V., He, Yaowu, Datta, Keshava K., Lu, Xue, Maheshwari, Uma R., Venkat, Pooja, Mayoh, Chelsea, Gowda, Harsha, Kalimutho, Murugan, Hooper, John D. and Khanna, Kum Kum (2023). Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma. Molecular Therapy, 31 (3) 212011, 729-743. doi: 10.1016/j.ymthe.2022.12.011 |
|
2023 Journal Article Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancerLyons, Nicholas, Giri, Rabina, Begun, Jakob, Clark, David A, Proud, David, He, Yaowu, Hooper, John and Kryza, Thomas (2023). Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer. Antioxidants and Redox Signaling, 39 (1-3), 186-205. doi: 10.1089/ars.2022.0127 |
|
2022 Conference Publication Development of antibody-drug conjugates targeting the CDCP1 receptor for the treatment of Triple negative and metastatic breast cancerGough, M., Kwah, K., Khan, T., He, Y., Pyke, C., Ratnayake, G., Snell, C., Hooper, J. and Kryza, T. (2022). Development of antibody-drug conjugates targeting the CDCP1 receptor for the treatment of Triple negative and metastatic breast cancer. 13th European Breast Cancer Conference (EBCC-13), Barcelona, Spain, 16-18 November 2022. Oxford, United Kingdom: Elsevier. doi: 10.1016/s0959-8049(22)01571-4 |
|
2022 Journal Article CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapyKhan, Tashbib, Lyons, Nicholas J., Gough, Madeline, Kwah, Kayden K.X., Cuda, Tahleesa J., Snell, Cameron E., Tse, Brian W., Sokolowski, Kamil A., Pearce, Lesley A., Adams, Timothy E., Rose, Stephen E., Puttick, Simon, Pajic, Marina, Adams, Mark N., He, Yaowu, Hooper, John D. and Kryza, Thomas (2022). CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy. Theranostics, 12 (16), 6915-6930. doi: 10.7150/thno.78171 |
|
2021 Journal Article Elevating CDCA3 levels enhances tyrosine kinase inhibitor sensitivity in TKI-resistant EGFR mutant non-small-cell lung cancerSahin, Katherine B., Shah, Esha T., Ferguson, Genevieve P., Molloy, Christopher, Kalita-de Croft, Priyakshi, Hayes, Sarah A., Hudson, Amanda, Colvin, Emily, Kamitakahara, Hannah, Harvie, Rozelle, Hasovits, Csilla, Khan, Tashbib, Duijf, Pascal H. G., Howell, Viive M., He, Yaowu, Bolderson, Emma, Hooper, John D., Lakhani, Sunil R., Richard, Derek J., O’Byrne, Kenneth J. and Adams, Mark N. (2021). Elevating CDCA3 levels enhances tyrosine kinase inhibitor sensitivity in TKI-resistant EGFR mutant non-small-cell lung cancer. Cancers, 13 (18) 4651, 4651. doi: 10.3390/cancers13184651 |
|
2021 Journal Article Preclinical molecular PET-CT imaging targeting CDCP1 in colorectal cancerCuda, Tahleesa J., He, Yaowu, Kryza, Thomas, Khan, Tashbib, Tse, Brian W., Sokolowski, Kamil A., Liu, Cheng, Lyons, Nicholas, Gough, Madeline, Snell, Cameron E., Wyld, David K., Rose, Stephen, Riddell, Andrew D., Stevenson, Andrew R. L., Thomas, Paul A., Clark, David A., Puttick, Simon and Hooper, John D. (2021). Preclinical molecular PET-CT imaging targeting CDCP1 in colorectal cancer. Contrast Media and Molecular Imaging, 2021 3153278, 3153278. doi: 10.1155/2021/3153278 |
|
2021 Journal Article Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian CancerHe, Yaowu, Khan, Tashbib, Kryza, Thomas, Jones, Martina L., Goh, Justin B., Lyons, Nicholas J., Pearce, Lesley A., Lee, Michael D, Gough, Madeline, Rogers, Rebecca, Davies, Claire M,, Gilks, C. Blake, Hodgkinson, Thomas, Lourie, Rohan, Barry, Sinead C., Perrin, Lewis C., Williams, Charlotte C., Puttick, Simon, Adams, Timothy E., Munro, Trent P., Hooper, John D. and Chetty, Naven (2021). Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer. Molecular Pharmaceutics, 18 (9) acs.molpharmaceut.1c00401, 3464-3474. doi: 10.1021/acs.molpharmaceut.1c00401 |
|
2021 Journal Article Extracellular vesicle transmission of chemoresistance to ovarian cancer cells is associated with hypoxia-induced expression of glycolytic pathway proteins, and prediction of epithelial ovarian cancer disease recurrenceAlharbi, Mona, Lai, Andrew, Sharma, Shayna, Kalita-De Croft, Priyakshi, Godbole, Nihar, Campos, America, Guanzon, Dominic, Salas-Burgos, Alexis, Carrion, Flavio, Zuñiga, Felipe A., Perrin, Lewis, He, Yaowu, Pejovic, Tanja, Winters, Carmen, Morgan, Terry, Hooper, John D., Rice, Gregory E. and Salomon, Carlos (2021). Extracellular vesicle transmission of chemoresistance to ovarian cancer cells is associated with hypoxia-induced expression of glycolytic pathway proteins, and prediction of epithelial ovarian cancer disease recurrence. Cancers, 13 (14) 3388, 1-26. doi: 10.3390/cancers13143388 |
|
2021 Journal Article Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1Kryza, Thomas, Khan, Tashbib, Lovell, Scott, Harrington, Brittney S., Yin, Julia, Porazinski, Sean, Pajic, Marina, Koistinen, Hannu, Rantala, Juha K., Dreyer, Tobias, Magdolen, Viktor, Reuning, Ute, He, Yaowu, Tate, Edward W. and Hooper, John D. (2021). Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1. Nature Chemical Biology, 17 (7), 776-783. doi: 10.1038/s41589-021-00783-w |
|
2021 Journal Article The CDCP1 signalling hub: a target for cancer detection and therapeutic interventionKhan, Tashbib, Kryza, Thomas, Lyons, Nicholas J., He, Yaowu and Hooper, John D. (2021). The CDCP1 signalling hub: a target for cancer detection and therapeutic intervention. Cancer Research, 81 (9) canres.2978.2020, QF1-QF11. doi: 10.1158/0008-5472.can-20-2978 |
|
2021 Journal Article A nucleotide analog prevents colitis associated cancer via Β-catenin independently of inflammation and autophagySheng, Yong Hua, Giri, Rabina, Davies, Julie, Schreiber, Veronika, Alabbas, Saleh, Movva, Ramya, He, Yaowu, Wu, Andy, Hooper, John, McWhinney, Brett, Oancea, Iulia, Kijanka, Gregor, Hasnain, Sumaira, Lucke, Andrew J., Fairlie, David P., McGuckin, Michael A., Florin, Timothy H. and Begun, Jakob (2021). A nucleotide analog prevents colitis associated cancer via Β-catenin independently of inflammation and autophagy. Cellular and Molecular Gastroenterology and Hepatology, 11 (1), 33-53. doi: 10.1016/j.jcmgh.2020.05.012 |
|
2020 Other Outputs Substrate-biased activity-based probes identify the urokinase-plasminogen axis as a master regulator of metastatic signaling by orphan membrane receptor CDCP1Kryza, Thomas, Khan, Tashbib, Lovell, Scott, Harrington, Brittney S., Yin, Julia, Porazinski, Sean, Pajic, Marina, Koistinen, Hannu, Rantala, Juha, Dreyer, Tobias, Magdolen, Viktor, Reuning, Ute, He, Yaowu, Tate, Edward and Hooper, John David (2020). Substrate-biased activity-based probes identify the urokinase-plasminogen axis as a master regulator of metastatic signaling by orphan membrane receptor CDCP1. |
|
2020 Other Outputs Binding proteins to CUB domain-containing protein (CDCP1)Puttick, S., Kryza, T., Hooper, J. D., He, Y., Harrington, B., Quigley, J. and Deryugina, E. (2020). Binding proteins to CUB domain-containing protein (CDCP1). PCT/AU2020/051216. |
